TOP1 consists of four domains:
N-terminal domain (1–213): Variable and unstructured, involved in protein interactions .
Core domain (214–635): Contains the capping (CAP) and catalytic (CAT) modules that entrap DNA .
Linker domain (636–712): Flexible region connecting the core to the C-terminal domain .
C-terminal domain (713–765): Houses the catalytic tyrosine residue (Y723) for DNA cleavage .
It cleaves one DNA strand, enabling rotation to relieve torsional stress .
Re-ligation restores DNA integrity. Aborted reactions leave TOP1 covalently linked to DNA (TOP1cc), causing toxic lesions .
Resolves supercoils ahead of replication forks and RNA polymerase II (RNAPII) during transcription .
Prevents transcription-replication conflicts (TRCs) that lead to R loops and double-strand breaks (DSBs) .
TOP1 is a primary target for anticancer drugs like camptothecin, topotecan, and irinotecan . These inhibitors stabilize TOP1cc, converting transient DNA breaks into lethal DSBs during replication .
TOP1-Targeted Drugs | Mechanism | Clinical Use |
---|---|---|
Camptothecin derivatives | Stabilize TOP1cc | Colorectal, ovarian cancers |
Indenoisoquinolines | Intercalate DNA-TOP1 complex | Experimental therapies |
Autism spectrum disorders: TOP1 regulates transcriptional elongation at long genes implicated in neurodevelopment .
Spinocerebellar ataxia (SCAN1): Mutations in TOP1 repair enzyme TDP1 cause neurodegeneration .
TOP1ccs induce R loops and micronuclei, particularly during early S phase, exacerbating genomic instability in cancer cells .
RNase H1 overexpression mitigates TOP1cc-induced micronuclei, suggesting therapeutic strategies .
A mitochondrial isoform (52% identity with nuclear TOP1) maintains mitochondrial DNA integrity .
Dysregulation linked to metabolic disorders and chemotherapy resistance .
TOP1 suppressors: Compounds like LMP744 disrupt TOP1-DNA binding, reducing toxicity in sepsis models .
SUMOylation: Post-translational modifications regulate TOP1 activity at transcriptionally active regions, limiting DNA damage .
Human TOP1 is a monomeric enzyme that resolves topological problems in DNA by transiently cleaving one strand of the DNA duplex. The enzyme introduces a single-strand break via transesterification at a target site, forming a DNA-(3'-phosphotyrosyl)-enzyme intermediate and releasing a 5'-OH DNA strand . This action allows the free DNA strand to rotate around the intact strand, relieving torsional stress that accumulates during processes like replication and transcription.
Methodologically, researchers studying TOP1's basic function should employ:
In vitro DNA relaxation assays using supercoiled plasmid DNA
Cleavage complex detection methods
Cellular assays measuring the consequences of TOP1 inhibition or depletion
TOP1 differs from other human topoisomerases in several key aspects:
Feature | Human TOP1 | Human TOP2 | Human Mitochondrial TOP1 (top1mt) |
---|---|---|---|
Structure | Monomeric | Dimeric | Monomeric with mitochondrial targeting sequence |
DNA cleavage | Single-strand | Double-strand | Single-strand |
ATP requirement | No | Yes | No |
Subcellular localization | Nuclear | Nuclear | Mitochondrial |
Gene | TOP1 | TOP2A/TOP2B | TOP1MT |
To study these differences experimentally, researchers should:
Use specific inhibitors (camptothecins for TOP1, etoposide for TOP2)
Generate specific knockdown models for each enzyme
Employ subcellular fractionation techniques to isolate mitochondrial versus nuclear topoisomerase activities
Human TOP1 comprises several functional domains that contribute to its catalytic activity:
N-terminal domain: Contains nuclear localization signals and sites for protein-protein interactions
Core domain: Responsible for DNA binding and contains residues important for catalysis
Linker domain: Connects the core and C-terminal domains, allowing conformational flexibility
C-terminal domain: Contains the catalytic tyrosine residue (Tyr723) that forms the covalent bond with DNA
For structural studies of TOP1, researchers should consider:
X-ray crystallography of TOP1-DNA complexes with and without inhibitors
Site-directed mutagenesis of key residues to assess functional importance
Domain deletion/swapping experiments to determine domain-specific functions
Several complementary approaches can be used to measure TOP1 activity:
Assay Type | Principle | Advantages | Limitations |
---|---|---|---|
Plasmid Relaxation | Electrophoretic separation of supercoiled vs. relaxed DNA | Simple, quantitative | Low throughput |
DNA Cleavage | Detection of covalent TOP1-DNA complexes | Directly measures cleavage | Requires radiolabeling for sensitivity |
ELISA-based | Quantitative detection of TOP1 protein | High throughput, sensitive to 0.37ng/mL | Measures protein, not activity |
Fluorescence-based | Real-time monitoring using fluorescent substrates | Real-time kinetics, no gel required | Specialized equipment needed |
For optimal results, researchers should:
Include appropriate controls (positive, negative, and enzyme titration)
Standardize reaction conditions (buffer composition, temperature, DNA substrate quality)
Consider the intra-assay CV (reported as 4.5% for ELISA methods) and inter-assay CV (7.4%)
Creating reliable TOP1 depletion models requires careful consideration of TOP1's essential nature:
RNAi approaches: Stable expression of siRNA targeting TOP1 has successfully created cell lines with ~5-fold reduction in TOP1 levels (e.g., HCT116-siTop1 and MCF-7-siTop1) .
Validation requirements:
Phenotypic characterization:
TOP1's role in genomic stability has been demonstrated through multiple lines of evidence:
Stable TOP1-depleted cell lines (HCT116-siTop1 and MCF-7-siTop1) exhibit:
These observations suggest that proper TOP1 function is critical for maintaining genomic integrity, and its dysregulation may contribute to cancer development through increased mutation rates and chromosomal instability.
Research strategies to study this connection include:
Long-term culture of TOP1-depleted cells to track accumulation of mutations
Analysis of TOP1 status in precancerous lesions versus advanced tumors
Correlation of TOP1 activity with genomic instability markers in patient samples
Camptothecin (CPT) is a plant alkaloid that specifically targets TOP1 through a well-characterized mechanism:
CPT binds to the TOP1-DNA complex after the enzyme has cleaved one DNA strand
It prevents the religation step, stabilizing the covalent TOP1-DNA complex
These stabilized complexes collide with advancing replication forks, creating DNA double-strand breaks
The resulting DNA damage rapidly blocks both DNA and RNA synthesis
Beyond CPT, various natural compounds interact with TOP1 at different stages of its catalytic cycle:
Terpenoids, flavonoids, stilbenes, and fatty acids can interfere with binding, cleavage, rotation, or religation processes
These compounds offer potential leads for developing new TOP1-targeting therapeutics
Methodologically, researchers studying TOP1 inhibitors should:
Employ multiple assay types to characterize inhibition mechanisms
Test compounds in both biochemical and cellular assays
Determine structure-activity relationships
Assess specificity through comparison with effects on other topoisomerases
TOP1 exhibits numerous non-canonical functions beyond its enzymatic DNA nicking-closing activity. To investigate these functions:
Experimental approaches:
Case study: TOP1 regulation of asparagine synthetase (ASNS) expression
This demonstrates how researchers can identify gene-specific transcriptional regulation by TOP1 through a combination of genomic and functional approaches.
Proper experimental design for TOP1 research requires rigorous controls:
Control Type | Examples | Purpose |
---|---|---|
Expression controls | Wild-type cells, complemented knockdown cells, catalytically inactive mutants | Distinguish enzymatic from structural functions |
Treatment controls | Vehicle controls, time-matched controls, concentration series | Ensure specificity of observed effects |
Validation controls | Multiple siRNA sequences, rescue experiments, cross-cell line validation | Rule out off-target effects |
Compensation controls | TOP2α activity measurements, DNA damage response monitoring | Account for cellular adaptations |
Researchers should be particularly aware that TOP2α compensates for TOP1 deficiency in stable knockdown lines , which may confound interpretation of results if not properly accounted for.
Several common pitfalls affect TOP1 research data interpretation:
Ignoring compensatory mechanisms: TOP2α upregulation in TOP1-depleted cells can mask phenotypes .
Failing to distinguish direct from indirect effects: Effects observed after TOP1 inhibition may be several steps removed from TOP1's direct action.
Overlooking timing considerations: Acute versus chronic TOP1 depletion can yield different phenotypes.
Data inconsistencies: When contradictory results emerge across experimental systems, researchers must systematically evaluate:
Cell type differences
Experimental methodologies
Extent of TOP1 inhibition/depletion
Presence of replication stress
Inappropriate statistical analysis: Given the complex nature of TOP1 function, researchers should:
When comparing TOP1 expression or activity across different datasets:
Standardization considerations:
Normalize to appropriate housekeeping genes/proteins
Account for cell proliferation rates (highly proliferative cells typically have elevated TOP1)
Consider post-translational modifications that may affect activity
Context-dependent interpretation:
TOP1 changes may reflect adaptation to cellular stress
Expression changes may not correlate with activity changes
Subcellular localization is as important as total expression
Integration with highly cited research:
Advanced technologies are transforming TOP1 research in living cells:
Live-cell imaging approaches:
Single-molecule techniques:
Optical/magnetic tweezers to study TOP1-mediated DNA relaxation in real-time
Super-resolution microscopy to visualize TOP1 clustering at specific genomic sites
Genomic approaches:
TOP1 ChIP-seq to map genomic binding sites
TOP1cc sequencing to identify preferred cleavage sites
Integration with transcriptome data to correlate TOP1 activity with gene expression
Researchers adopting these techniques should carefully validate them against established biochemical assays and consider both their advantages and limitations when interpreting results.
When faced with contradictory TOP1 findings:
Systematic comparison approach:
Create a comprehensive table of experimental conditions
Identify key variables that differ between studies
Design targeted experiments to test specific hypotheses about discrepancies
Integrated model development:
Formulate models that can accommodate seemingly contradictory observations
Test predictions of these models in multiple systems
Refine models based on new experimental data
Collaborative resolution:
Establish collaborations between laboratories with divergent findings
Implement standardized protocols and reagents
Perform blinded cross-validation studies
TOP1 is a nuclear enzyme that plays a vital role in maintaining the supercoiling and torsional tension of DNA. It achieves this by transiently cleaving and rejoining one strand of the DNA duplex. The enzyme introduces a single-strand break via a transesterification reaction at a target site in the DNA. This allows the free DNA strand to rotate around the intact phosphodiester bond on the opposing strand, thereby removing DNA supercoils .
The enzyme’s catalytic activity involves the formation of a DNA-(3’-phosphotyrosyl)-enzyme intermediate, which is crucial for the relaxation of supercoiled DNA molecules . This process is essential for normal DNA replication and transcription, as it prevents the formation of knots and tangles in the DNA that could otherwise impede these processes .
TOP1 is essential for normal cellular development and transcriptional regulation. It is involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter . Additionally, TOP1 regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells .
Variants in the TOP1 gene have been associated with various diseases, including hematologic cancers and spinocerebellar ataxia . The enzyme is also a target antigen for Scl-70 autoantibodies, which are associated with systemic sclerosis .
Recombinant DNA Topoisomerase-I is produced using recombinant DNA technology, which involves inserting the human TOP1 gene into a suitable expression system, such as bacteria or yeast. This allows for the large-scale production of the enzyme for research and therapeutic purposes .
Recombinant TOP1 is used in various biochemical assays to study its function and interactions with other molecules. It is also employed in drug discovery efforts aimed at identifying inhibitors of TOP1, which could be potential therapeutic agents for treating cancers and viral infections .
TOP1 inhibitors, such as camptothecin and its derivatives, are used as chemotherapeutic agents due to their ability to stabilize the TOP1-DNA complex, leading to DNA damage and cell death in rapidly dividing cancer cells . Additionally, research has shown that TOP1 can repress HIV-1 promoter activity through its interaction with a guanine quadruplex present in the LTR sequence, offering new perspectives for anti-viral strategies .